Two Sigma Advisers
AMLX icon

Two Sigma Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History

Two Sigma Advisers’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-328,401
Closed -$3.97M – 110
2025
Q4 		$3.97M Buy
328,401
+185,401
+130% +$2.52M 0.01% 921
2025
Q3 		$1.94M Sell
143,000
-327,000
-70% -$3.08M ﹤0.01% 1151
2025
Q2 		$3.01M Sell
470,000
-179,800
-28% -$875K 0.01% 938
2025
Q1 		$2.3M Buy
649,800
+408,400
+169% +$1.45M 0.01% 1102
2024
Q4 		$912K Sell
241,400
-68,100
-22% -$320K ﹤0.01% 1508
2024
Q3 		$1M Sell
309,500
-844,700
-73% -$1.9M ﹤0.01% 1413
2024
Q2 		$2.19M Buy
1,154,200
+355,300
+44% +$689K ﹤0.01% 1142
2024
Q1 		$2.27M Buy
+798,900
New +$10.4M 0.01% 1152

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Two Sigma Advisers's AMLX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 328,401 shares — an estimated $3.97M sold.

Two Sigma Advisers first reported a position in AMLX in Q1 2024 and held it in 8 quarters. The position peaked at $3.97M in Q4 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 328,401 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $3.97M.
  • Two Sigma Advisers first reported a position in Amylyx Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Two Sigma Advisers's Amylyx Pharmaceuticals position peaked at $3.97M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.